Intelligence · Clinical Development
Pipeline search results
Programs matching “zanubrutinib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 31 pipeline programs matching "zanubrutinib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
NHL-014
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Diffuse Large B-Cell Lymphoma
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
B-cell malignancies
1 trial -
Zanubrutinib
BeiGene
B-cell Malignancies
2 trials -
Zanubrutinib
BeiGene
Chronic Lymphocytic Leukemia
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Relapsed/Refractory Follicular Lymphoma
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Primary Membranous Nephropathy
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
B-cell Malignancies
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia
2 trials -
zanubrutinib
BEONE MEDICINES AUS PTY LTD
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
1 trial -
BDH-CLL-002-2022/02/14
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Lymphocytic Leukemia
1 trial -
OBINUTUZUMAB, Zanubrutinib
BeiGene
Relapsed/Refractory Follicular Lymphoma
1 trial -
Zanubrutinib
Wuhan Createrna Science and Technology Co., Ltd
Cold agglutinin disease
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Diffuse Large B-cell Lymphoma (DLBCL)
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Follicular Lymphoma
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Mantle Cell Lymphoma
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
Mature B-cell Malignancies
1 trial -
Zanubrutinib
The First People's Hospital of Lianyungang
Chronic Lymphocytic Leukemia
1 trial -
Zanubrutinib
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
Zanubrutinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
1 trial -
Zanubrutinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Mantle Cell Lymphoma
1 trial -
Zanubrutinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory/Relapsed Autoimmune Hemolytic Anemia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.